Skip to content

Fast Antidepressant Efficacy and Central Mechanisms of Single Low-Dose Ketamine Injection in Treating Major Depression: a double-blind and randomized-controlled trial and image study

Fast Antidepressant Efficacy and Central Mechanisms of Single Low-Dose Ketamine Injection in Treating Major Depression: a double-blind and randomized-controlled trial and image study - Single Low-Dose Ketamine Injection in Treating Major Depression

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000016985
Enrollment
72
Registered
2016-06-30
Start date
2014-12-31
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment-resistant depression, TRD

Interventions

Ketamine 0.5mg/kg Ketamine 0.2mg/kg PBO

Sponsors

Ministry of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: diagnosis of major depressive disorder according to Diagnostic and Statistical Manual of Mental Disorders-IV-Text Revision (DSM-IV-TR)

Exclusion criteria

Exclusion criteria: 1) Use of CNS intoxicant within the previous 24 hours or urine toxicology screen positive for drugs of abuse 2) Overdose, within previous 24 hours, of any agent which would compromise ketamine metabolism 3) Symptoms of substance abuse/dependence(except nicotine dependence) within 6 months 4) Lifetime use of ketamine or phencyclidine(PCP) 5) Diagnosis of psychosis or bipolar disorder

Design outcomes

Primary

MeasureTime frame
PET MRI MADRS

Countries

Asia(except Japan)

Contacts

Public ContactCheng-Ta Li

Taipei Veterans General Hospital Psychiatry

on5083@msn.com+81-1886228757027

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026